Table 1.

Demographics and baseline characteristics of patients in the efficacy population of GO-MORE

Patient characteristics	n = 3280
Demographic characteristics
Female, n (%)	2716 (82.8)
Age, median (min, max), years	53.0 (18, 88)
Disease characteristics
Disease duration, years	n = 3279
Median (min, max)	4.9 (0.01, 56.6)
TJC28, mean (s.d.)	13.0 (6.81)
SJC28, mean (s.d.)	9.6 (5.56)
DAS28-ESR	n = 3270
Moderate disease activity (3.2–5.1), n (%)	698 (21.3)
High disease activity (>5.1), n (%)	2572 (78.7)
Mean (s.d.)	5.97 (1.095)
DAS28-CRP	n = 3236
Mean (sd)	5.41 (0.998)
CRP, mg/l	n = 3236
Mean (s.d.)	14.48 (20.376)
ESR, mm/h	n = 3280
Mean (s.d.)	34.9 (24.64)
Anti-CCP	n = 3225
Positive (≥20 U/ml), n (%)	2318 (71.9)
RF	n = 3234
Positive (≥15 IU/ml), n (%)	2344 (72.5)
HAQ-DI, mean (s.d.)	1.44 (0.67)

Table adapted from Combe B, Dasgupta B, Louw I, et al. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. Ann Rheum Dis 2014;73:1477–86 [13]. with permission © (2004) BMJ publishing group. SJC28: joint swollen joint count 28; TJC28, joint tender joint count 28; n: number.